Clinical Trial Update: Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients [Phase 2]

View source ↗

Summary

An extension of a Phase II trial of a humanized non-mitogenic anti-CD3 monoclonal antibody (ChAgly CD3) in recently diagnosed Type 1 diabetes patients has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• ChAgly CD3 (ChAgly CD3)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: COMPLETED